Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic International has initiated dosing in its Phase 1 clinical trial for the DYAI-100 COVID-19 booster vaccine candidate. This trial, conducted in South Africa, aims to evaluate the vaccine's clinical safety and antibody response in healthy volunteers aged 18-55. Following regulatory approval from SAHPRA in late 2022, the trial will consist of 15 subjects per cohort with a total randomization scheme of 4:1. Dosing is expected to complete within the first quarter of 2023, with results projected later this year. This marks the first human trial utilizing Dyadic’s C1 protein production platform, highlighting potential advancements in COVID-19 vaccine development.
Dyadic International, Inc. (NASDAQ: DYAI) announced a receipt of approximately $1.27 million from the sale of its equity interest in Alphazyme LLC. This investment came as part of a licensing agreement whereby Dyadic granted a non-exclusive license to its technology. The agreement allows Dyadic to receive milestone and royalty payments from Alphazyme's sales of C1 expressed products, plus potential additional payments based on future sales of Alphazyme's existing products. Dyadic is focused on biopharmaceutical innovations for human and animal health, leveraging its C1-cell technology and other platforms.
Dyadic International will participate in the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12, 2023, in San Francisco, CA. CEO Mark Emalfarb will present on January 8, focusing on advancements in Dyadic's C1-cell protein expression platform and its first Phase 1 clinical trial, expected to commence this month. Emalfarb will discuss the efficacy of C1-produced COVID-19 ferritin nanoparticle vaccines, supported by data from respected institutions.
Dyadic International announced the publication of a study demonstrating its vaccine candidate DYAI-100, a recombinant protein RBD booster for COVID-19, has shown promise in animal models. The study, published in VACCINES, supports the upcoming First-In-Human clinical trial aimed at evaluating safety and immune response. The vaccine demonstrated strong immunogenicity and antiviral efficacy without adverse effects. Importantly, the C1-cell production platform offers a cost-effective and scalable manufacturing process, reinforcing Dyadic's commitment to producing affordable biopharmaceuticals.
Dyadic International received regulatory approval from SAHPRA to initiate a Phase 1 clinical trial for its COVID-19 vaccine candidate, DYAI-100. The company presented significant data at the World Vaccine Congress Europe and announced new collaborations in animal health. As of September 30, 2022, cash and investments totaled $14.2 million. Research and development revenues increased to approximately $880,000 for Q3 2022. Net loss for the quarter was about $1.8 million, consistent with the prior year, but the loss per share improved over nine months.
Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced participation in key industry events in November 2022, aimed at enhancing its microbial platforms for protein production and biopharmaceutical needs. Key conferences include the RAFT® 14 Conference (Nov 6-9) in Orlando, where CEO Mark Emalfarb will present on Nov 8. Additionally, Dyadic will join the BARDA Industry Day (Nov 15-16) virtually and the Jefferies London Healthcare Conference (Nov 16-19). These events focus on connecting with investors and showcasing advancements in biopharmaceutical products.
Dyadic International, Inc. (NASDAQ: DYAI) will report its third quarter 2022 financial results and conduct a corporate update call on November 10, 2022, at 5:00 PM ET. The company focuses on innovative microbial platforms to enhance global protein production and develop affordable biopharmaceuticals for human and animal health. Its proprietary technologies include the C1-cell protein production platform and Dapibus™ for large-scale manufacturing of proteins. Dyadic aims to expedite the development of biologic products, including its DYAI-100 COVID-19 vaccine candidate.
Dyadic International (NASDAQ: DYAI) has received regulatory approval from the South African Health Products Regulatory Authority for a Phase 1 clinical trial of its DYAI-100 COVID-19 booster vaccine. This randomized, double-blind, placebo-controlled trial will assess the vaccine's safety and preliminary efficacy, with patient enrollment set to begin in South Africa later this year. Dyadic's CEO, Mark Emalfarb, expressed optimism about this milestone, while the partner Rubic Consortium emphasized its significance for improving vaccine access in underserved regions.
Dyadic International (NASDAQ: DYAI) announced that its CEO, Mark Emalfarb, will present at the World Vaccine Congress from October 11-14, 2022 in Barcelona, Spain. The presentation will showcase advancements in expressing Omicron BA.5 and other antigens, aiming to enhance vaccine efficacy against viruses, including COVID-19 variants. Notably, the C1-cell platform allows for efficient antigen production at 10 grams per liter. Collaboration with Dr. Albert Osterhaus will also be highlighted. Interested parties can register for the event or request meetings.
Dyadic International, Inc. (NASDAQ: DYAI) provided updates on its C1 protein production platform, showcasing advancements in protein yield and overall productivity. Key achievements include a nine-fold increase in the expression yield for Nivolumab, and successful expression of several COVID-19 variants, including Omicron. The C1 platform demonstrated significant potential for accelerating vaccine development and lowering production costs. The company anticipates data presentations at upcoming industry conferences and details a planned Phase 1 clinical trial for its COVID-19 recombinant protein booster vaccine.